2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Johnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.Peer-Reviewed Original ResearchExpression of immune checkpointsClinical activityNeoadjuvant cisplatinImmune checkpointsT cellsIncreased expression of immune checkpointsTranscriptome RNA sequencingMuscle-invasive patientsPegfilgrastim 6 mgAggressive histologic subtypePathological complete responseUrothelial bladder cancerT cell genesBasal-squamousYpCR rateNeoadjuvant therapyComplete responseHistological subtypesSingle-institutionUrothelial cancerPrimary endpointUrothelial tumorsTumor biologyBladder cancerGrade 3
2009
Predictors of Survival After Resection of Retroperitoneal Sarcoma
Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, Choti MA, Pawlik TM. Predictors of Survival After Resection of Retroperitoneal Sarcoma. Annals Of Surgery 2009, 250: 970-976. PMID: 19644351, PMCID: PMC3099434, DOI: 10.1097/sla.0b013e3181b25183.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantInfant, NewbornKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPostoperative PeriodPrognosisProportional Hazards ModelsRetroperitoneal NeoplasmsRetrospective StudiesRisk FactorsSarcomaSEER ProgramSurvival RateTime FactorsUnited StatesYoung AdultConceptsPrimary retroperitoneal sarcomaRetroperitoneal sarcomaPredictors of survivalAJCC staging systemTumor sizeStaging systemRPS resectionHistological subtypesCurrent AJCC staging systemPatients Undergoing ResectionDiscriminatory abilityEnd Results (SEER) databaseAmerican Joint CommitteeCancer (AJCC) staging systemLymph node metastasisModerate discriminatory abilityMalignant fibrous histiocytomaProportional hazards modelPoor discriminatory abilityPrevalent histologyUndergoing resectionNode metastasisAJCC stageMultivariable analysisResults database